2018 年 35 巻 4 号 p. 495-497
Cybernic functional regeneration treatment using Hybrid Assistive Limb (HAL) may become a new standard treatment for all neurological ambulation disorders such as neuromuscular. The NCY–3001 clinical trial for neuromuscular diseases including spinal muscular atrophy (SMA), spinal and bulbar muscular atrophy (SBMA), amyotrophic lateral sclerosis (ALS), muscular dystrophy, Charcot–Marie Tooth disease (CMT), distal myopathy, sporadic inclusion body myositis, and congenital myopathy was completed, and HAL was approved as a new medical device in 2015. According to the results of this RCT to test the short–term efficacy and safety, cybernic treatment using HAL started to be covered by Japanese health insurance in April 2016, and Cyberdyne Inc. released this system in September 2016. Clinical trials for the other neurological disorders including spastic paraplegia (NCY–2001). We have much experience of long–term efficacy of cybernic treatment in the neuromuscular diseases in the real world data. This cybernic treatment can be combined with other treatments including drug, oligonucleotide, antibody and stem cell therapies.
